<DOC>
	<DOC>NCT02229747</DOC>
	<brief_summary>The objective of this study was to assess the clinical efficacy and safety of meloxicam suspension 0.25 mg/kg/day once a day, versus diclofenac suspension 1 mg/kg/day twice a day or nimesulide suspension 4 mg/kg/day twice a day, after five days of treatment in patients with a diagnosis of acute, non-bacterial pharyngitis, pharyngotonsillitis or laryngitis</brief_summary>
	<brief_title>Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis</brief_title>
	<detailed_description />
	<mesh_term>Pharyngitis</mesh_term>
	<mesh_term>Laryngitis</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Nimesulide</mesh_term>
	<criteria>Patients of both genders between 2 and 8 years old Outpatients, with onset of symptoms not more than 72 hours prior to presentation, patients with acute nonbacterial pharyngitis or pharyngotonsillitis diagnosed according to the following criteria: Spontaneous pharyngeal pain, pharyngeal pain upon swallowing, pharyngeal and/or tonsillar hyperemia, absence of purulent plaques, pharyngeal smear negative for ßhemolytic Streptococcus or Strepto Test® and Treatment with an Nonsteroidal antiinflammatory drugs (NSAID) required or recommended Known or suspected hypersensitivity to study medications or NSAID's Pharyngeal smear positive for ßhemolytic Streptococcus treatment with antimicrobials prior to enrolment in the study Chronic infection, infectious mononucleosis, peptic ulcer disease that has been active in the previous 6 months Asthma nasal polyps angioneurotic edema or urticaria after the administration of aspirin or NSAID's Concomitant treatment with anticoagulants (including heparin), lithium or methotrexate Concomitant administration of other NSAID's (including high dose aspirin) or analgesics, except authorized rescue drugs Administration of any NSAID during the three previous days or of analgesics within six hours prior to the administration of the first study drug dose Treatment with corticosteroids at the time of enrollment or within the two previous months Known liver, renal or hematological disease Participation in another clinical trial during the study period or during the previous month Previous enrollment in this study Inability to comply with the protocol Suspected acute bacterial pharyngitis or pharyngotonsillitis (under the following clinical criteria): Clinical presentation characterized by a rapid onset, very high fever (&gt;38.5°C), severe pharyngeal pain, cervical adenopathy, intense headache, purulent pharyngeal plaques, evidence of peritonsillar abscess or phlegmon</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>